<DOC>
	<DOCNO>NCT02589275</DOCNO>
	<brief_summary>This Phase 3 , open-label , extension trial design evaluate long term safety efficacy 3 month TNX-102 SL tablet take daily bedtime treatment Fibromyalgia ( FM ) . Patients recruit trial successfully complete double-blind study ; TNX-CY-F301 TNX-CY-F302 . Anticipated start TNX-CY-F302 March 2016 . Patients make aware therapy receive double-blind study .</brief_summary>
	<brief_title>A 3-Month Open-Label Safety Efficacy Study TNX-102 SL Tablets Fibromyalgia Patients</brief_title>
	<detailed_description>The study consist 4 study visit , include Screening/Baseline Visit 1 ( Day 0 , anticipate date Visit 6 F301 F302 ) visit 1 , 2 3 month treatment ( Visits 2-4 ) . Primary : The primary objective study evaluate safety TNX-102 SL tablet take daily bedtime additional 3 month patient FM complete double-blinded lead-in study Secondary : The secondary objective evaluate efficacy TNX-102 SL tablet take daily bedtime control symptoms FM</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Cyclobenzaprine</mesh_term>
	<criteria>The patient meet prior inclusion exclusion requirement study F301 F302 originally , intervene medical condition , increase suicidal ideation , requirement concomitant medication preclude exposure TNX102 SL enrollment extension study . The patient complete expect dose F301 F302 define take study medication Week 12 , least 70 % compliance medication usage ( base overall drug accountability reconciliation end F301 F302 leadin study ) major protocol deviation . The patient provide write informed consent participate extension protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>TNX-102 SL</keyword>
	<keyword>bedtime</keyword>
	<keyword>sublingual</keyword>
	<keyword>3-month</keyword>
	<keyword>long term safety</keyword>
	<keyword>long term efficacy</keyword>
	<keyword>Fibromyalgia</keyword>
</DOC>